Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (496)	8/27/1999 5:58:00 PM
From: Biomaven	Read Replies (3) \| Respond to of 717

Well 35 didn't last for long ... Some options activity (not a clue what it means, if anything): Headline: OPTIONS-Pharmacyclics vols up,3Com business tapers ====================================================== CHICAGO, Aug 27 (Reuters) - Implied volatility stayed firm Friday in options on Pharmacyclics Inc. (NASDAQ:PCYC), while Thursday's burst of business tapered off in 3Com Corp. (NASDAQ:COMS). Implied vols for Pharmacyclics September 35 calls rose to 107 percent, with the puts near 117 percent, both just above the more usual range of between about 90-105 percent, said an options strategist. "So it's (volatility) usually high," he said. "It kind of looks like they're buying September and selling December." But volume in the Philadelphia Stock Exchange option stayed very light, totaling about 137 calls and 10 puts on Friday. Shares of the California-based developer of cancer-related drugs gave back intraday gains Friday and ended flat at 33-1/4 on Nasdaq market volume of 194,500. Pharmacyclics stock had risen steadily since closing August 17 at 26-1/2. Pretty hefty volatilities - for someone who is less optimistic than I, selling covered calls might be a good strategy. Peter